August Troendle Sells 5,534 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 5,534 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $601.53, for a total value of $3,328,867.02. Following the completion of the transaction, the chief executive officer owned 633,412 shares of the company’s stock, valued at $381,016,320.36. The trade was a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Medpace Price Performance

Medpace stock opened at $581.95 on Friday. The stock has a market cap of $16.24 billion, a P/E ratio of 34.11, a PEG ratio of 2.66 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm’s 50 day moving average price is $533.75 and its 200-day moving average price is $491.74.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the firm earned $3.10 earnings per share. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MEDP. Royal Bank Of Canada lifted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and raised their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $584.18.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. Johnson Financial Group Inc. purchased a new position in shares of Medpace in the 2nd quarter worth approximately $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC bought a new stake in Medpace in the fourth quarter worth $30,000. Allied Private Wealth LLC bought a new stake in Medpace in the second quarter worth $31,000. Finally, Kilter Group LLC purchased a new position in Medpace during the second quarter worth $31,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.